PRTN3 and arthritic joint disease: The finding that a substantial proportion of ACPA-negative RA patients, as determined by three commercial assays, shows reactivity in the multiplex assay is intriguing and prompted us to determine whether this assay has an additive value over “conventional” ACPA testing in an “early arthritis setting”.